Shattuck Labs, Inc. (STTK)
NASDAQ: STTK · Real-Time Price · USD
7.43
+0.34 (4.80%)
At close: Jul 24, 2026, 4:00 PM EDT
7.52
+0.09 (1.21%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Shattuck Labs Revenue
In the year 2025, Shattuck Labs had annual revenue of $1.00M, down -82.52%.
Revenue (ttm)
$1.00M
Revenue Growth
-82.52%
P/S Ratio
569.74
Revenue / Employee
$25,000
Employees
40
Market Cap
569.74M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.00M | -4.72M | -82.52% |
| Dec 31, 2024 | 5.72M | 4.06M | 245.26% |
| Dec 31, 2023 | 1.66M | 1.01M | 154.14% |
| Dec 31, 2022 | 652.00K | -29.37M | -97.83% |
| Dec 31, 2021 | 30.02M | 20.08M | 202.16% |
| Dec 31, 2020 | 9.93M | 47.00K | 0.48% |
| Dec 31, 2019 | 9.89M | -12.56M | -55.94% |
| Dec 31, 2018 | 22.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arvinas | 89.40M |
| 4D Molecular Therapeutics | 88.24M |
| Verastem | 49.59M |
| Adlai Nortye | 5.00M |
| Prime Medicine | 4.03M |
| Silence Therapeutics | 839.00K |
| Altimmune | 36.00K |
STTK News
- 1 day ago - Shattuck Labs initiated with an Overweight at JPMorgan - TheFly
- 5 days ago - Shattuck Labs initiated with an Outperform at Leerink - TheFly
- 5 days ago - Shattuck Labs initiated with an Outperform at Leerink - TheFly
- 11 days ago - Shattuck Labs Slides: Corporate presentation - Filings
- 6 weeks ago - Shattuck Labs 10.9M share Spot Secondary priced at $4.00 - TheFly
- 6 weeks ago - Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering - GlobeNewsWire
- 6 weeks ago - Shattuck Labs TBA Spot Secondary; price range $4.00-$4.25 - TheFly
- 6 weeks ago - Shattuck Labs announces common stock offering, no amount given - TheFly